Clinical Trial

Latigo Biotherapeutics' new drug LTG-001 shows superior, faster pain relief than Vicodin in a major trial, offering a potent new tool against the opioid crisis.

The FNIH is launching a landmark study using AI and biomarkers to redefine depression, moving beyond guesswork toward precision care for millions.

A new study suggests A2-protein infant formula may boost growth, a potential game-changer. But with preliminary data, experts urge caution.

Lantern Pharma's EMA-cleared trial for LP-184 uses a dual-biomarker strategy, targeting a multi-billion dollar market where patient options are scarce.

Dasher Neuroscience completes Phase 2 enrollment for its AI-designed drug for MSA, a fatal disease with no cure, signaling a major step toward a first-in-class therapy.

An Australian biotech's breakthrough study on fucoidan, a seaweed compound, offers a safe, clinically-proven new option for men suffering from BPH.

A breakthrough BCI not only restores movement and sensation but promotes lasting change. Joyce Watson analyzes how Neuvotion is turning science into a business.

An upcoming summit for LGMD isn't just another conference. It's a key signal that patient advocacy, biotech innovation, and regulatory shifts are converging.

FDA clears a pivotal study for Medicus Pharma's SkinJect, a microneedle patch offering new hope for Gorlin Syndrome and a new playbook in biotech strategy.

Small biotech Veru Inc. is betting its future on improving blockbuster weight-loss drugs, targeting the hidden cost of muscle loss in a billion-dollar market.

Pacira BioSciences de-risks its promising knee osteoarthritis gene therapy by solving the manufacturing puzzle, a key step from lab to market for millions.

A breakthrough trial for a rare genetic disorder unlocks $50M in funding. We explore the novel RNA science, the savvy investment, and why it's all happening in Australia.

Promising early data for BBT001 suggests a potent combination of rapid relief and quarterly dosing, but can the biotech startup navigate the long road from pilot to production?

With a billion people globally struggling with sleep apnea and CPAP compliance low, Incannex Healthcare is advancing its oral drug IHL-42X, now in a key Phase 2 study.

Bio-Thera Solutions has begun a Phase 1 trial for BAT8013, a novel ADC targeting CD25 to deplete immunosuppressive cells in the tumor microenvironment.

Beam Therapeutics is set to unveil pivotal data for its AATD gene editor. Success could transform a disease and validate a multi-billion-dollar platform.

A new heart valve from Venus Medtech can be fully deployed and retrieved, giving surgeons an 'undo' button that could revolutionize patient safety.

A new clinical trial combines two targeted therapies, offering potential hope for kidney cancer patients who have exhausted even the newest treatment options.

Spryte Medical's novel nOCT system offers microscopic views inside brain vessels. With its pivotal clinical trial enrollment complete, it's a step closer to FDA approval.